- Mateo, Joaquin;
- McKay, Rana;
- Abida, Wassim;
- Aggarwal, Rahul;
- Alumkal, Joshi;
- Alva, Ajjai;
- Feng, Felix;
- Gao, Xin;
- Graff, Julie;
- Hussain, Maha;
- Karzai, Fatima;
- Montgomery, Bruce;
- Oh, William;
- Patel, Vaibhav;
- Rathkopf, Dana;
- Rettig, Matthew;
- Schultz, Nikolaus;
- Smith, Matthew;
- Solit, David;
- Sternberg, Cora;
- Van Allen, Eliezer;
- VanderWeele, David;
- Vinson, Jake;
- Soule, Howard R;
- Chinnaiyan, Arul;
- Small, Eric;
- Simons, Jonathan W;
- Dahut, William;
- Miyahira, Andrea K;
- Beltran, Himisha
Despite advances in prostate cancer screening and treatment, available therapy options, particularly in later stages of the disease, remain limited and the treatment-resistant setting represents a serious unmet medical need. Moreover, disease heterogeneity and disparities in patient access to medical advances result in significant variability in outcomes across patients. Disease classification based on genomic sequencing is a promising approach to identify patients whose tumors exhibit actionable targets and make more informed treatment decisions. Here we discuss how we can accelerate precision oncology to inform broader genomically-driven clinical decisions for men with advanced prostate cancer, drug development and ultimately contribute to new treatment paradigms.